Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021201035
Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.5 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.76 | |||||
| Beneish M-Score | -4.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -81.7 | |||||
| 3-Year EBITDA Growth Rate | 15.3 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 25.6 | |||||
| 3-Year Book Growth Rate | -20.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.61 | |||||
| 9-Day RSI | 32.46 | |||||
| 14-Day RSI | 36.89 | |||||
| 6-1 Month Momentum % | 58.54 | |||||
| 12-1 Month Momentum % | -9.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.27 | |||||
| Quick Ratio | 6.27 | |||||
| Cash Ratio | 5.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -79.1 | |||||
| Shareholder Yield % | -68.93 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -15557.79 | |||||
| Net Margin % | -14274.5 | |||||
| FCF Margin % | -10605.1 | |||||
| ROE % | -52.86 | |||||
| ROA % | -41.23 | |||||
| ROIC % | -297.71 | |||||
| ROC (Joel Greenblatt) % | -399.52 | |||||
| ROCE % | -50.67 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 270 | |||||
| PB Ratio | 1.12 | |||||
| Price-to-Tangible-Book | 1.12 | |||||
| EV-to-EBIT | -0.49 | |||||
| EV-to-Forward-EBIT | -0.38 | |||||
| EV-to-EBITDA | -0.52 | |||||
| EV-to-Forward-EBITDA | -0.38 | |||||
| EV-to-Revenue | 76.47 | |||||
| EV-to-Forward-Revenue | 5.14 | |||||
| EV-to-FCF | -0.72 | |||||
| Price-to-Net-Current-Asset-Value | 1.39 | |||||
| Price-to-Net-Cash | 1.48 | |||||
| Earnings Yield (Greenblatt) % | -204.08 | |||||
| FCF Yield % | -34.44 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers